The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $91.53

Today's change+3.35 +3.80%
Updated December 26 4:00 PM EST. Delayed by at least 15 minutes.
 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $91.53

Today's change+3.35 +3.80%
Updated December 26 4:00 PM EST. Delayed by at least 15 minutes.

Biomarin Pharmaceutical Inc crosses above 20-day moving average

Biomarin Pharmaceutical Inc closed up sharply Friday, rallying (U.S.)$3.35 or 3.80% to (U.S.)$91.53 and crossing above its 20-day moving average. Shares have lost 2.46% over the last five days, but have gained 30.11% over the last year to date. This security has outperformed the S&P 500 by 17.87% during the last year.

Key company metrics

  • Open(U.S.) $88.86
  • Previous close(U.S.) $88.18
  • High(U.S.) $91.74
  • Low(U.S.) $88.09
  • Bid / Ask-- / --
  • YTD % change+30.11%
  • Volume572,725
  • Average volume (10-day)1,299,670
  • Average volume (1-month)1,203,574
  • Average volume (3-month)1,193,908
  • 52-week range(U.S.) $55.04 to (U.S.) $96.36
  • Beta0.94
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.88
Updated December 26 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-18.91%

Biomarin Pharmaceutical Inc has a net profit margin of -18.91%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.10%Sector:HealthcareIndustry:Pharmaceuticals - Generic & Specialty
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue177192152147
Total other revenue--------
Total revenue177192152147
Gross profit147161129122
Total cost of revenue30312325
Total operating expense166211178200
Selling / general / administrative79686071
Research & development1261088697
Depreciation / amortization11112
Interest expense (income), net operating--------
Unusual expense (income)-68103
Other operating expenses, total238-9
Operating income11-20-26-53
Interest income (expense), net non-operating-9-9-9-8
Gain (loss) on sale of assets--------
Other--------
Income before tax3-28-35-59
Income after tax7-34-38-62
Income tax, total-4633
Net income7-34-38-62
Total adjustments to net income--------
Net income before extra. items7-34-38-62
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items7-34-38-62
Inc. avail. to common incl. extra. items7-34-38-62
Diluted net income8-34-38-62
Dilution adjustment000--
Diluted weighted average shares159146144143
Diluted EPS excluding extraordinary itemsvalue per share0.05-0.23-0.26-0.43
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.23-0.23-0.26-0.42